Pesquisar
PepGen Inc
PEPGAdicionar à lista de desejos
2.980USD
0.0000.00%
Horário de mercado 09/14, 13:22（ET）
206.39MValor de mercado
PerdaP/L TTM
Mais detalhes de PepGen Inc Empresa
PepGen Inc. is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies. The Company’s Enhanced Delivery Oligonucleotide (EDO) platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases. It is focused on addressing the underlying cause of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), which have high unmet need. Its pipeline consists of two clinical stage programs, PGN-EDO51 for DMD patients who are amenable to an exon 51-skipping approach and PGN-EDODM1 for DM1 patients, and several additional preclinical stage programs. Its product candidates also include PGN-EDO53, PGN-EDO45 and PGN-EDO44.
PepGen Inc Perfil
Código da empresaPEPG
Nome da EmpresaPepGen Inc
Data de listagemMay 06, 2022
CEOMcArthur (James G)
Número de funcionários81
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 06
Endereço245 Main St, 2nd Floor
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02142
Telefone17034568000
Sitehttps://pepgen.com
Código da empresaPEPG
Data de listagemMay 06, 2022
CEOMcArthur (James G)
Executivos da empresa PepGen Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. James G. McArthur, Ph.D.
Dr. James G. McArthur, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
63.10K
+15.70%
Dr. James G. McArthur, Ph.D.
Dr. James G. McArthur, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
63.10K
+15.70%
Mr. Noel P. Donnelly
Mr. Noel P. Donnelly
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Joshua B. (Josh) Resnick, M.D.
Dr. Joshua B. (Josh) Resnick, M.D.
Independent Director
Independent Director
--
--
Ms. Heidi Henson, CPA
Ms. Heidi Henson, CPA
Independent Director
Independent Director
--
--
Ms. Laurie Bartlett Keating, J.D.
Ms. Laurie Bartlett Keating, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Habib Joseph Dable
Mr. Habib Joseph Dable
Independent Director
Independent Director
--
--
Dr. Howard Mayer, M.D.
Dr. Howard Mayer, M.D.
Independent Director
Independent Director
--
--
Dr. Paul D. Streck, M.D.
Dr. Paul D. Streck, M.D.
Executive Vice President, Head of Research and Development
Executive Vice President, Head of Research and Development
--
--
Dr. Mitchell H. Finer, Ph.D.
Dr. Mitchell H. Finer, Ph.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. James G. McArthur, Ph.D.
Dr. James G. McArthur, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
63.10K
+15.70%
Dr. James G. McArthur, Ph.D.
Dr. James G. McArthur, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
63.10K
+15.70%
Mr. Noel P. Donnelly
Mr. Noel P. Donnelly
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Joshua B. (Josh) Resnick, M.D.
Dr. Joshua B. (Josh) Resnick, M.D.
Independent Director
Independent Director
--
--
Ms. Heidi Henson, CPA
Ms. Heidi Henson, CPA
Independent Director
Independent Director
--
--
Ms. Laurie Bartlett Keating, J.D.
Ms. Laurie Bartlett Keating, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de PepGen Inc?
Os cinco principais acionistas de PepGen Inc são: Dr. James G. McArthur, Ph.D.
Quantas instituições possuem ações da PepGen Inc (PEPG)?
Em 2026Q1, 209 instituições possuíam ações da PepGen Inc, com valor de mercado aproximado de 66.38M, representando 95.96% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -2071901.00.